Self‐Assembled Acid‐Responsive Nanosystem for Synergistic Anti‐Angiogenic/Photothermal/Ferroptosis Therapy against Esophageal Cancer

Abstract

Esophageal cancer (EC) treatment via anti‐angiogenic therapy faces challenges due to non‐cytotoxicity and non‐specific biodistribution of the anti‐angiogenic agents. Hence, the quest for a synergistic treatment modality and a targeted delivery approach to effectively address EC has become imperative. In this study, an acid‐responsive release nanosystem (Bev‐IR820@FeIIITA) that involves the conjugation of bevacizumab, an anti‐angiogenic monoclonal antibody, with TA and Fe3+ to form a metal‐phenolic network, followed by loading with the near‐infrared photothermal agent (IR820) to achieve combinational therapy, is designed. The construction of Bev‐IR820@FeIIITA can be realized through a facile self‐assembly process. The Bev‐IR820@FeIIITA exhibits tumor‐targeting capabilities and synergistic therapeutic effects, encompassing anti‐angiogenic therapy, photothermal therapy (PTT), and ferroptosis therapy (FT). Bev‐IR820@FeIIITA exhibits remarkable proficiency in delivering drugs to EC tissue through its pH‐responsive release properties. Consequently, bevacizumab exerts its therapeutic effects by obstructing tumor angiogenesis, thereby impeding tumor growth. Meanwhile, PTT facilitates localized thermal ablation at the tumor site, directly eradicating EC cells. FT synergistically collaborates with PTT, giving rise to the formation of a reactive oxygen species (ROS) storm, subsequently culminating in the demise of EC cells. In summary, this amalgamated treatment modality carries substantial promise for synergistically impeding EC progression and showcases auspicious prospects for future EC treatment.

Association between plasma circulating tumor DNA and the prognosis of esophageal cancer patients: a meta-analysis

“…Typically, the disease manifests at an advanced stage upon presentation 4 , 5 . Despite considerable progress in treatment strategies over recent decades, the prognosis for EC remains frustrating, with a consistent 5-year survival rate remaining below 30% 6 , 7 . Therefore, the identification of a specific prognostic indicator is imperative for enhancing the outcomes of EC patients.…”

CuNCs-Based pH-Responsive Degradable Nanoplatform for Enhanced CDT/IIT Synergistic Tumor Therapy in a “One-Stone-Two-Birds” Manner

“…At present, CDT has gained prominence as a therapeutic method due to its economic feasibility, high efficiency, simplicity, and independence from external energy sources such as light, sound, or heat. − Studies have found that in addition to Fe 2+ , other metal ions such as Mn 2+ , Cu + , Co 2+ and V 2+ also has excellent CDT ability. − In recent years, copper nanoclusters (CuNCs) have garnered significant attention as fluorescent nanomaterials in the fields of analytical chemistry and bioimaging. , However, there is limited research on utilizing CuNCs as Fenton metal sources for catalyzing the production of ·OH in CDT and simultaneously for cellular imaging to locate the materials. The valence states of copper in the cluster primarily exist as Cu­(I) and Cu(0), enabling the catalysis of ·OH generation from H 2 O 2 in the TME .…”